Dateline City:
WHITEHOUSE STATION, N.J.
GRASTEK (Timothy Grass Pollen Allergen Extract) Remains Under FDA Review in the United States
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the regulatory approval and launch of GRASTEK
(Timothy grass pollen allergen extract) sublingual tablets in Canada.
This represents the first approval of GRASTEK for Merck. The product is
currently marketed by ALK-Abello in Europe as GRAZAX.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more